Singapore markets closed

Organon & Co. (OGN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
28.76-0.91 (-3.07%)
As of 02:01PM EST. Market open.
Sign in to post a message.
  • C
    Ctahoot
    A PE of 5 with a womens pharma stock and an ageing population…go figure…I just keep buying. oh and let’s not forget the 3 1/2 divided
  • c
    c
    Falling Knife? I wanted some at $30 when it was selling for $31 now I'm glad my order didn't fill. Great current PE with a decent Yield but the trend says there's something negative that management hasn't emphasized.
  • J
    Jakob
    Looks like price wants to fill the gap at $30. Should find some support there, I would guess.
  • g
    gary
    Yeah baby!!! This company is the easiest short ever. You longs better sell now? this #$%$ is heading for 5 bucks!
  • h
    hirsct
    Total dividend trap, I fall for all of’em.
    attracted to a high yield and after 6 months the stock’s down 30%
  • H
    Howie
    It is worth watching the conversation with Kevin Ali and Matthew Walsh for the virtual Evercore ISI healthcare conference....https://wsw.com/webcast/evercore21/ogn/2164536
  • L
    Lisa
    Picked some up at 32.07. Quite the drop in the last 6 days, I'm betting it's an overreaction.
  • c
    c
    Why are quarterly earnings expected to decrease? Average estimate by 6 analysts is $1.31 for Q4 2021. What would cause earnings to decrease from the Q3 amount of $1.67?
  • F
    FILIP
    OGN: This stock has been down every day since the last earnings reported on 11-11-2021.
    Reasons: Warren Buffett has been selling each time OGN 's price trying to recover.
    Buffett is now sold off all his 1.6 millions of OGN shares. The OGN sell-off was so excessive and
    it is due for a rebound....Be patient....It will come back to $35 by either end of Nov 2021 or by December 2021
    the latest...
  • F
    FILIP
    OGN STOCK will go Ex-dividend tomorrow and record date: 11-22-2021. Need to buy today in order to
    get the quarterly dividend payment of: .28 cents. Many money managers and mutual fund will most
    likely buy this stock today.....I am a buyer of OGN stock today as this stock has been oversold including
    today's sell off....The reward is huge!!
  • J
    Jakob
    MRK dividend moving higher today. I think OGN should get much more aggressive about raising their dividend, or demonstrate an ability to really start paying down debt. This is not a growth stock. I think they should be returning value directly to shareholders. Stock buyback would be fine, too, but I would prefer a higher dividend. Just targeting a 50% payout would put the divi at about $3 and then yield over 10% at current share prices.
  • C
    C
    Ogn is still very profitable and its fundamentals are solid, with Women's Health and Biosimilars presenting promising growth— Biosimilars grew 41% to 140 million. Valuation shows that Ogn is trading below fair value by more than 20%. The sell off is a buy the dip opportunity as it remains a solid value Buy and will be a quality money maker stock for long term.
  • c
    chet
    were the earnings that bad that its down 10%?
  • j
    js
    Organon (NYSE:OGN): Q3 Non-GAAP EPS of $1.67 beats by $0.23;
    GAAP EPS of $1.27 beats by $0.07.
    Revenue of $1.6B (-0.6% Y/Y) beats by $10M.

    FY21 Guidance: Revenue of $6.2B-$6.3B from prior guidance of $6.1B-$6.4B vs. $6.29B consensus

    Good earnings. And they bought a new company that creates a medicament for endometriotic lesions.
  • H
    Howie
    Berkshire sells out of Organon and Merck and paired down Abbvie.
  • H
    Howie
    If the company can show growth of high single digits running into a Hadlima (Humira biosimilar) launch in the US in 2023, I would expect a multiple of 10 to 12. If that is the case we should be looking at a 60 to 70 share price in the next 24 months.
  • d
    dick
    Now is the time to double your position------------way too cheap on a forward PE of 5.5x's
  • H
    Howie
    I plan to sell 56K of APPL stock over 170 and pick up 2K of OGN before the end of the year.
  • d
    dick
    This quarter,s epd of $1.67, if sustainable translates into $ 6.68 eps/annum.
    Should see upgrades to $55 PT
  • E
    Ed
    I interpreted at leas some of the price action to be an overreaction to the acquistion of Forendo - I for one like it. Although reported to be 954 million that's only if Fordendo current compounds are (wildly?) successful. Looks to be < 100 million upfront and < 400 million for clinical milestones, the other 500 million "commercial" milestones being presumably dependent on actual sales. Perhaps ther is a risk that this is ultimately a failed attempt to buy some growth but I don't see it 954 million being spent unless there is some commercial success. IMHO some irrational action to the perceived lack of growth and this attempt to add some growth to the top line in the future. Seriously, isn't this deal a modest and reasonable use of some of the cash flow?